All News

🛑Doing Hands and feet Xray in undifferentiated arthritis? Retro study 700+pts shows: ✔️only few patients w/ UA present w/ RA-associated erosions at presentation ✔️Rarely leads to change in diagnosis or prognosis. Will you stop? I probably won't 👀 @RheumNow #EULAR23 OP0172 https://t.co/BRpmDqaN0r

#Lupus #nephritis - many trials and this is one company #Roche and other #pharmaceutical CO’s are also involved #Hope #SLE #EULAR2023 ⁦@RheumNow⁩ ⁦@eular_org⁩ https://t.co/Giu2iUqq6j

The steroid dosing in SAPHYR (sarilumab in PMR): Bottom two trajectories: sarilumab protocol & actual Top two trajectories: placebo protocol & actual Fascinating that with sarilumab, more PNL only really in play at PNL <3mg/d. Def takes the heat out POS0715 #EULAR2023 @RheumNow https://t.co/aEC8cQaR7O

RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its Faculty.

• Erdheim-Chester disease (ECD) is associated with Langerhans cell histiocytosis (LCH) • Bone pain, xanthelasma, hairy kidney • Differential diagnoses of LCH • BRAF mutation associated with cardiac and neurological phenotype of ECD Haroche J, Papo M #EULAR2023 @RheumNow https://t.co/AzKJKp82nq

What do we do with PMR patients with subclinical GCA seen on ultrasound? Well, in these non-blinded cohorts the subclinical GCA pts got more pred. Was it warranted? Hard to say. If we’re going to look for it, let’s try and figure out what it means POS0712 #EULAR2023 @RheumNow https://t.co/KmCcE0Nsu9

Rx of #lupus #SLE The most challenging seems to be longstanding & residual disease activity - damage accumulates over time - esp if #glucocorticoids are used. Consider only as bridging. How to treat #lupus #EULAR2023 Boumpas ⁦@RheumNow⁩ #ClinicalPearl ⁦@eular_org⁩ https://t.co/heBbcRAjxO

I mean, if proteomics is more your jive for GCA, we’ve got that too here at #EULAR2023. Definite potential for phenotyping a disease with diverse outcomes POS0694 @RheumNow https://t.co/tSWpZlUPoE

Could mitochondria play a role in the pathogenesis of Sjogrens disease?! #Eular2023 https://t.co/XndW4qFf3E

Malt lymphoma in Sjogrens disease and role of PET scan. When is PET scan suggestive? Follow: Complement RF Focus score SPEP #Eular2023 https://t.co/60l8iRNvQN

Just a reminder: nr-axSpA isn’t destined to become r-axSpA/AS. Life is more complicated than that. Between the natural history and TNFi, very small conversion rate post-10y. Of course, whatever the x-rays, it can still disable though DESIR cohort POS0675 #EULAR2023 @RheumNow https://t.co/29HeJXpK2S

Very early days, but it’s cool to see transcriptomics in GCA ➡️ in situ spatial profiling ➡️ drug-gene interactions ➡️ new therapeutic targets identified. Only time will tell if they will work, but very cool nevertheless. POS0091 (Mayo, La Jolla, & INSERM) #EULAR2023 @RheumNow https://t.co/n7raIENVOT

I’ve been hearing the term ´Jackies’ used in talks on Jak inhibitors. A shorter form of JAKinibs or JAKi #EULAR2023 @RheumNow

In Brazil, if you’re in the early RA clinic (yellow bars) you do a lot better than other academic clinics, even w bDMARD access. Maybe it’s early Rx, or love & care, or other patient factors - but it’s a reminder that RA isn’t a level playing field. POS0055 #EULAR2023 @RheumNow https://t.co/jI2dvuIHWP

The interface between cutaneous lymphoma and lupus panniculitis, characteristic differences and diagnostic algorithm, Eviatar T, #EULAR2023 @RheumNow https://t.co/HRTQWS4Ctq

Do we use too much PNL in GCA (when not using TCZ)? Could we wean quicker? Salvarini group n=22 26w PNL weaning protocol from GiACTA, but no TCZ 10/26 in relapse free remission at 1y Much less PNL, still some steroid AEs Way of the future for some? POS0728 #EULAR2023 @RheumNow https://t.co/qeZHeCi9vq

Tapering pred in RA - this just rings true from everyday clinic life. Some patients just seem to hit a wall at PNL 2.5. Sometimes it’s GC withdrawal arthralgias/tertiary adrenal insufficiency, but often it’s genuine inflammation. I still wonder why? POS0050 #EULAR2023 @RheumNow https://t.co/JBh26VqPuM

#EULAR2023 #POS0120 From Sjogren to SLE. Interim analysis of Phase 2 RCT showed primary endpoint, SRI-4 + ability to sustain pred dose to ≤5 mg/d or ≤ BL from Wk16 to 28 was achieved more in Ianalumab (Bcell depletion & BAFF-R-i) vs PBO (44% vs 9%). Advance to Phase 3 @RheumNow https://t.co/Wg29uj5yqv

Can machine learning help bDMARD selection in RA? Early days limited by the data available, so not great yet, but efforts underway are a good start for an area where we need to do better than our status quo guessing. Watch this space POS0641 #EULAR2023 @RheumNow https://t.co/2j8H40iFWo

You need to see this! Albert with a Left V1 distribution of #shingles is a ‘bot’ who interacts with #rheumatologists at #EULAR2023 ⁦@RheumNow⁩ ⁦@eular_org⁩ #artificial #intelligence https://t.co/gDwzc3NX7v

Topics

All News

Do you get our email newsletter?